We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MedImmune and Avalon Pharmaceuticals have announced a collaboration to discover
and develop small molecule therapeutic compounds in the area of inflammatory
disease.
Seattle Genetics has entered into an agreement under which it will license its
proprietary antibody-drug conjugate (ADC) technology to PSMA Development (PDC),
a joint venture between Progenics Pharmaceuticals and Cytogen.
Researchers from the University of Bologna, Italy, have demonstrated that Thal-Dex
(thalidomide used in combination with dexamethasone) is more powerful than conventional
chemotherapy for the treatment of multiple myeloma.
A group of researchers led by Applied NeuroSolutions' founding scientist Peter
Davies, has identified an abnormal type of cell division that appears to be
a critical part of the chain of events that results in Alzheimer's disease.
Researchers investigating recurrent miscarriages have discovered that the steroid
prednisolone reduces the numbers of a type of cell that is known to play a role
before and during early pregnancy.
A four-year study using a prospectively structured clinical database to assess
comparative efficacy and safety of multiple sclerosis therapies, demonstrated
that patients with relapsing-remitting multiple sclerosis treated with Copaxone
(glatiramer acetate injection) showed superior relapse rate reduction than those
treated with beta interferon therapies.
Monitoring and fine tuning the levels of the cancer drug topotecan in children
with neuroblastoma holds promise for maximizing the drug's effectiveness while
reducing its toxicity, according to investigators at St. Jude Children's Research
Hospital.
Dendreon has completed enrollment in its Phase III PROTECT clinical trial of
Provenge in men with non-metastatic androgen-dependent (hormone-sensitive) prostate
cancer.
BioCryst Pharmaceuticals has announced that the FDA has granted "fast-track"
status to the development of Fodosine, for the treatment of relapsed or refractory
T-cell leukemia.
Solvay Pharmaceuticals and CV Therapeutics has announced that the FDA has informed
Solvay Pharmaceuticals that the FDA has extended the Prescription Drug User
Fee Act (PDUFA) date for the ACEON (perindopril erbumine) tablets supplemental
new drug application by 90 days, and the PDUFA date is now Sept. 10, 2005.